Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Wedbush analyst Laura Chico maintained a Hold rating on Biogen today and set a price target of $191.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Chico is a 5-star analyst with an average return of 12.3% and a 51.37% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.
In addition to Wedbush, Biogen also received a Hold from Barclays’s Emily Field in a report issued today. However, on the same day, H.C. Wainwright reiterated a Buy rating on Biogen (NASDAQ: BIIB).
Based on Biogen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.28 billion and a GAAP net loss of $48.41 million. In comparison, last year the company earned a revenue of $2.45 billion and had a net profit of $266.7 million
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year. Most recently, in February 2026, Priya Singhal, the Head of Development of BIIB sold 2,660.00 shares for a total of $531,547.80.
Read More on BIIB:
Disclaimer & DisclosureReport an Issue
- Biogen price target raised to $237 from $228 at H.C. Wainwright
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Biogen price target raised to $275 from $250 at Oppenheimer
- Biogen price target raised to $245 from $230 at Canaccord
- Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio
